Finance

Lists
BLAU3:BVMF
Blau Farmaceutica SA
R$12.30
0.00%
(0.00) 1D
Oct 13, 5:04:00 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BLAU3...
Mkt. cap
2.87B
Avg. vol.
292.48K
Volume
0.00
Dividend
5.64%
Quarterly dividend
R$0.17
Ex-dividend date
Dec 19, 2025
P/E ratio
12.27
52-wk high
R$12.89
52-wk low
R$8.22
EPS
R$1.00
Shares outstanding
233.21M
No. of employees
2K
Mkt. cap
2.87B
Avg. vol.
292.48K
Volume
0.00
Dividend
5.64%
Quarterly dividend
R$0.17
Ex-dividend date
Dec 19, 2025
P/E ratio
12.27
52-wk high
R$12.89
52-wk low
R$8.22
EPS
R$1.00
Shares outstanding
233.21M
No. of employees
2K
News stories
From web sources and news partners
About Blau Farmaceutica SA
CEOMarcelo Rodolfo Hahn
Employees1.9K
Founded1987
Headquarters-
SectorBiotechnology
Websiteblau.com
Last report
Aug 12, 2026
Fiscal period
Q2 2026
R$0.31 / R$0.33
-8.01%miss
Revenue / Est. (BRL)
486.60M / 497.66M
-2.22%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in BRL
Loading Previous Earnings...
Revenue
Net income
All values in BRL
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
475.20M
389.36M
434.97M
486.60M
Cost of goods sold
282.46M
235.99M
254.72M
274.60M
Cost of revenue
282.46M
235.99M
254.72M
274.60M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
90.17M
100.07M
94.55M
100.58M
Operating expense
101.15M
104.83M
95.01M
128.66M
Total operating expenses
383.61M
340.82M
349.73M
403.25M
Operating income
91.59M
48.54M
85.24M
83.34M
Other non operating income
-
-2.58M
-2.87M
-
EBT including unusual items
138.33M
44.19M
52.20M
65.45M
EBT excluding unusual items
138.33M
44.19M
52.20M
65.45M
Income tax expense
32.81M
6.81M
15.92M
9.91M
Effective tax rate
23.72%
15.41%
30.49%
15.15%
Other operating expenses
10.98M
4.76M
461.00K
28.08M
Net income
104.42M
36.25M
39.77M
53.39M
Net profit margin
21.97%
9.31%
9.14%
10.97%
Earnings per share
0.53
-
0.17
0.31
Interest and investment income
106.52M
9.95M
12.94M
18.65M
Interest expense
-59.77M
-22.99M
-21.35M
-36.54M
Net interest expenses
46.75M
-13.04M
-8.41M
-17.89M
Depreciation and amortization charges
-
-
-
-
EBITDA
103.32M
62.47M
99.62M
98.53M
Gain or loss from assets sale
-
50.02M
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps